SCHEMBL16398907

SCHEMBL16398907

Cc1sc(-c2ccc(Cl)cc2)nc1C=O

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR2B P41595 1/20 0.51
RAB9A P51151 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
KDM4E B2RXH2 2/20 0.49
POLB P06746 2/20 0.49
NPC1 O15118 1/20 0.49
APEX1 P27695 1/20 0.46
CASP3 P42574 1/20 0.45
SENP8 Q96LD8 1/20 0.45
SENP7 Q9BQF6 1/20 0.45
SENP6 Q9GZR1 1/20 0.45
HRH3 Q9Y5N1 4/20 0.45
ALDH1A1 P00352 3/20 0.44
KMT2A Q03164 3/20 0.44
MAPT P10636 3/20 0.44
GAA P10253 2/20 0.44
MEN1 O00255 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
TRPM8 Q7Z2W7 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18002844 0.83 HTR2B (0.48) HTR2BRAB9AKDM4ENPC1ALDH1A1
SCHEMBL16399903 0.82 HTR2B (0.45) HTR2BRAB9ASMN1; SMN2KDM4EPOLB
SCHEMBL18003948 0.81 HTR2B (0.47) HTR2BRAB9ASMN1; SMN2KDM4EPOLB
SCHEMBL18003656 0.81 MAPT (0.54) HTR2BRAB9ASMN1; SMN2KDM4ENPC1
SCHEMBL16399400 0.80 ALDH1A1 (0.44) RAB9ASMN1; SMN2KDM4EPOLBNPC1
SCHEMBL16398903 0.80 NPC1 (0.48) HTR2BRAB9ASMN1; SMN2KDM4ENPC1
SCHEMBL18003638 0.80 KDM4E (0.42) RAB9ASMN1; SMN2KDM4EPOLBNPC1
SCHEMBL18003577 0.80 RAB9A (0.42) RAB9ASMN1; SMN2KDM4EPOLBNPC1
SCHEMBL16399750 0.80 ALOX5 (0.46) RAB9ASMN1; SMN2KDM4EPOLBNPC1
SCHEMBL16399629 0.80 HRH3 (0.45) RAB9ASMN1; SMN2KDM4EPOLBNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4570313-A2 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2025-06-18 EP disclosed
EP-4219477-A1 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2023-08-02 EP disclosed
US-10626095-B2 Cyanotriazole compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-04-21 US disclosed
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2016-08-11 US disclosed
EP-3022199-A1 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2016-05-25 EP disclosed
WO-2015008872-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2015-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10626095-B2 Cyanotriazole compounds CS, PC, ACAT1 HTR2B 4755/4885RAB9A 4775/4885SMN1; SMN2 3834/4885
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS CS, PC, ACAT1 HTR2B 4755/4885RAB9A 4775/4885SMN1; SMN2 3834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.